Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Piperacillin-Tazobactam vs AMOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Community-acquired pneumonia,Nosocomial pneumonia,Septicemia,Febrile neutropenia (off-label),Bone and joint infections (off-label)
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis) due to susceptible streptococci, pneumococci, and H. influenzae,Lower respiratory tract infections (e.g., pneumonia, bronchitis) due to susceptible streptococci, pneumococci, and H. influenzae,Genitourinary tract infections (e.g., uncomplicated gonorrhea, cystitis) due to susceptible E. coli, P. mirabilis, and enterococci,Skin and skin structure infections due to susceptible streptococci, staphylococci, and E. coli,Helicobacter pylori eradication (as part of combination therapy),Lyme disease (early localized or early disseminated),Prophylaxis of infective endocarditis (dental procedures) in patients with certain cardiac conditions
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
Piperacillin undergoes minor hepatic metabolism; tazobactam is metabolized to a minor inactive metabolite. Both are primarily excreted unchanged in urine via glomerular filtration and tubular secretion.
Amoxicillin is primarily metabolized through hydrolysis of the beta-lactam ring to inactive penicilloic acid, accounting for 60-70% of the dose; about 10% is metabolized via hepatic pathways to amoxicilloic acid; renal excretion as unchanged drug is 60-80% via tubular secretion and glomerular filtration.
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in Cr Cl <30 m L/min.
Piperacillin: ~30% bound to albumin; Tazobactam: ~30% bound to albumin.
17-20%, primarily to albumin.
Piperacillin: ~0.18-0.3 L/kg; Tazobactam: ~0.2-0.3 L/kg. Distributes widely into tissues, including lung, kidney, bile, peritoneal fluid, and inflamed tissues.
0.3-0.4 L/kg; indicates distribution into total body water.
IV only; oral bioavailability negligible (not orally administered).
Oral: 75-90% (variable with food, decreased absorption); IM: near 100%.
Cr Cl 20-40 m L/min: 2.25 g IV every 6 hours; Cr Cl <20 m L/min: 2.25 g IV every 8 hours; hemodialysis: 2.25 g IV every 12 hours, plus 0.75 g after dialysis.
GFR 10-30 m L/min: 250-500 mg every 12 hours; GFR <10 m L/min: 250-500 mg every 24 hours; hemodialysis: 250-500 mg every 24 hours with an additional dose after dialysis.
No dosage adjustment required for hepatic impairment. Use caution in patients with hepatic encephalopathy or severe hepatic dysfunction.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B); caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Infants and children: 100 mg piperacillin/kg/dose IV every 6-8 hours (max 4 g piperacillin per dose); for pseudomonal infections, up to 200 mg/kg/dose IV every 6 hours.
Neonates ≤28 days: 25-30 mg/kg/day divided every 12 hours; Infants and children >28 days: 20-40 mg/kg/day divided every 8 hours; for otitis media: 50-90 mg/kg/day divided every 8-12 hours.
Start at the lower end of dosing; adjust primarily based on renal function. Monitor renal function closely and modify dose according to creatinine clearance.
No specific dose adjustment based solely on age; monitor renal function and adjust dose based on creatinine clearance (Cr Cl) as per renal adjustment guidelines; maintain adequate hydration.
No FDA black box warnings.
None
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Hematologic toxicity (neutropenia, thrombocytopenia) with prolonged therapy,Renal impairment requiring dose adjustment,Electrolyte disturbances (hypokalemia),Neuromuscular irritability or seizures with high doses or renal failure
Serious hypersensitivity reactions (anaphylaxis) can occur; contraindicated in patients with penicillin allergy,Clostridium difficile-associated diarrhea (CDAD) may occur, ranging from mild diarrhea to fatal colitis,Prolonged use may result in superinfection with resistant organisms,Hepatic dysfunction and cholestatic jaundice (rare),Skin rashes, including morbilliform rash (common in patients with mononucleosis),Decreased efficacy when used with bacteriostatic agents (e.g., tetracyclines, chloramphenicol),Use with caution in patients with renal impairment (Cr Cl <30 m L/min) due to increased risk of seizures with high doses
Known hypersensitivity to piperacillin, tazobactam, or any beta-lactam antibiotic,History of anaphylactic reaction to penicillins, cephalosporins, or carbapenems
Known hypersensitivity to amoxicillin, penicillins, or any component of the formulation,Mononucleosis (high incidence of morbilliform rash)
No significant food interactions; take with or without food. Avoid alcohol during therapy.
No significant food interactions; absorption is not altered by food. Avoid excessive alcohol as it may increase risk of GI side effects and hepatotoxicity (rare).
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is generally acceptable for serious infections.
Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and meta-analyses do not indicate an increased risk of major congenital malformations, preterm birth, or low birth weight. Use is acceptable if clinically indicated across all trimesters.
Piperacillin and tazobactam are excreted into human milk in low concentrations. M/P ratio for piperacillin is approximately 0.11. No adverse effects on nursing infants are anticipated. Use with caution, especially if breastfeeding a premature infant or one with renal impairment.
Amoxicillin is excreted into breast milk in small amounts, with an M/P ratio of approximately 0.02-0.05. The estimated dose to the infant is less than 1% of the maternal weight-adjusted dose. It is generally considered compatible with breastfeeding. However, potential risks include infant sensitization, diarrhea, and rash. Monitor for these effects.
No dose adjustment is routinely required for pregnancy alone. However, pregnancy-related increases in renal clearance may necessitate higher doses or more frequent administration for severe infections. Monitor clinical response and consider therapeutic drug monitoring.
Physiologic changes in pregnancy (e.g., increased renal blood flow, GFR, and volume of distribution) may reduce serum concentrations of amoxicillin. While standard dosing may be effective, some experts recommend using the higher end of the dosing range or more frequent dosing for severe infections. However, no specific dose adjustment is routinely required; clinical response should guide therapy.
Piperacillin-tazobactam (Zosyn) exhibits time-dependent killing; optimal efficacy requires frequent dosing (every 6 hours) with extended infusion (4 hours) for critically ill patients. Adjust dose for renal impairment; Cr Cl <20 m L/min: max 2.25 g every 8 hours. Monitor for bleeding risk due to platelet dysfunction at high doses. Contains sodium (2.79 m Eq per gram of piperacillin); caution in heart failure. Do not co-administer with aminoglycosides in same IV line; use separate sites.
Amoxicillin is a first-line agent for acute otitis media, streptococcal pharyngitis, and uncomplicated community-acquired pneumonia. It has a time-dependent killing mechanism; optimal efficacy requires maintaining serum concentrations above the MIC for >40% of the dosing interval. Dose adjustment is necessary for creatinine clearance <30 m L/min. It is compatible with clavulanate for beta-lactamase coverage. Rash during therapy may indicate non-allergic ampicillin rash (especially with viral infections) or true hypersensitivity; assess carefully.
Take this medication exactly as prescribed; do not skip doses even if feeling better.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.,This drug may cause diarrhea, nausea, or headache; contact your doctor if severe or persistent.,Inform your doctor if you have kidney disease, heart failure, or bleeding disorders.,Avoid alcohol while taking this medication to reduce risk of adverse effects.
Take exactly as prescribed; complete the full course even if you feel better.,May be taken with or without food; avoid large meals if GI upset occurs.,Report any rash, especially if accompanied by hives or difficulty breathing.,Do not use leftover antibiotics; discard after completing course.,Use additional contraception if on oral contraceptives (may reduce efficacy).,For suspension: shake well, measure dose with provided device, refrigerate and discard after 14 days.
"Tazobactam, a beta-lactamase inhibitor, may reduce the therapeutic efficacy of picosulfuric acid, a stimulant laxative, by altering gut microbiota composition and reducing bacterial enzymatic conversion of the prodrug to its active metabolite. This can lead to diminished laxative effect and inadequate bowel preparation for colonoscopy. Patients may experience suboptimal colonic cleansing, potentially compromising diagnostic accuracy."
"Tazobactam, a beta-lactamase inhibitor, may reduce the serum concentration of doxorubicin, an anthracycline antineoplastic agent, potentially decreasing its cytotoxic efficacy. This interaction is hypothesized to occur through tazobactam's induction of drug transporters such as P-glycoprotein, enhancing doxorubicin efflux and lowering intracellular accumulation. Reduced doxorubicin exposure could compromise therapeutic outcomes in cancer patients, increasing the risk of treatment failure."
"Tazobactam, a beta-lactamase inhibitor, can reduce the serum concentration of Netilmicin, an aminoglycoside antibiotic, potentially diminishing its bactericidal efficacy. This interaction likely occurs through physicochemical inactivation in vivo, where beta-lactam compounds form a covalent bond with the aminoglycoside's amino groups, reducing its antimicrobial activity. Clinically, this may lead to subtherapeutic aminoglycoside levels, treatment failure, or increased risk of infection progression, particularly in immunocompromised patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Piperacillin-Tazobactam vs AMOXIL, answered by our medical review team.
Piperacillin-Tazobactam is a Penicillin Antibiotic + Beta-Lactamase Inhibitor that works by Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.. AMOXIL is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Piperacillin-Tazobactam and AMOXIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Piperacillin-Tazobactam is: 3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.. The standard adult dose of AMOXIL is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Piperacillin-Tazobactam and AMOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Piperacillin-Tazobactam is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is . AMOXIL is classified as Category C. Penicillins, including amoxicillin, are generally considered low risk in pregnancy. Animal studies have not shown teratogenic effects. In humans, data from large cohort studies and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.